Can GLP-1 medicines help you live longer and healthier?
In large trials, GLP-1 medicines did more than lower weight. Semaglutide lowered the risk of heart attack, stroke and heart-related death in people with heart disease and excess weight, and lowered the risk of serious kidney events in people with diabetes and kidney disease. These trials studied people who already had a condition, so they don't show whether the medicines help healthy people live longer.
Reviewed by Darshan Patel, MD, Obesity medicine physician, on 2026-11-12. Next review 2027-05-11.
Book my consultation Video consultations with an Aayu Well physician. Most major insurance accepted, plus convenient cash pay options.
Why people call GLP-1s longevity medicine
You want more good years: energy for the people you love, a heart and kidneys that keep up, and fewer health scares along the way. GLP-1 medicines such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) became famous for weight loss. Then large trials started to look past the scale, at heart attacks, kidney damage, liver disease and sleep apnea. That's why you now hear them called longevity medicine.
Here's what those trials found, in plain language, and what they don't tell us yet.
What the trials show
Evidence grade B for the specific conditions below: large, well-run randomized trials in people, usually one per condition. For healthy people hoping to live longer, there are no trials to grade yet. How we grade evidence.
| Area | Trial | Who was studied | What happened |
|---|---|---|---|
| Heart attack and stroke | SELECT (semaglutide) | 17,604 adults 45 or older with heart disease and overweight or obesity, without diabetes | Over about 40 months, 6.5% had a heart attack, stroke or heart-related death, compared with 8.0% on placebo: a 20% lower risk |
| Kidneys | FLOW (semaglutide) | 3,533 adults with type 2 diabetes and chronic kidney disease | 24% lower risk of kidney failure, a drop of half or more in kidney function, or death from kidney or heart causes. Major heart events were 18% lower and deaths from any cause 20% lower |
| Liver | ESSENCE (semaglutide) | Adults with liver inflammation from fat (MASH) and moderate to advanced scarring; first 800 people analyzed | At 72 weeks, the liver inflammation resolved without worse scarring in 62.9%, compared with 34.3% on placebo. Scarring improved in 36.8%, compared with 22.4% |
| Heart failure | STEP-HFpEF (semaglutide) and SUMMIT (tirzepatide) | People with obesity and a common type of heart failure (preserved ejection fraction) | In STEP-HFpEF, symptoms and walking distance improved more than on placebo over a year. In SUMMIT, worsening heart failure events or heart-related death happened to 9.9%, compared with 15.3% on placebo |
| Sleep apnea | SURMOUNT-OSA (tirzepatide) | Adults with obesity and moderate to severe sleep apnea | Over a year, breathing pauses and shallow breaths fell by about 25 to 29 an hour, compared with about 5 an hour on placebo |
Several of these results are now on FDA labels:
- Heart: Wegovy is approved to lower the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and either obesity or overweight.
- Kidneys: Ozempic is approved to lower the risk of lasting loss of kidney function, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
- Liver: Wegovy injection has an accelerated approval for MASH with moderate to advanced liver scarring (stages F2 to F3), based on improvement in the liver disease and scarring.
- Sleep apnea: Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity.
What the trials don't show yet
- Healthy people. Every trial above enrolled people who already had a health condition. None tested GLP-1 medicines as a way for healthy people to live longer.
- Muscle. Part of the weight lost on these medicines is lean tissue, including muscle. Studies range from about 15% or less of the weight lost to 40% to 60%. Muscle matters for strength and independence as you age, so protecting it is part of the plan.
- Stopping. Weight often comes back after people stop, which a joint advisory from four obesity and nutrition societies lists among the main challenges of GLP-1 care.
Who these medicines are for
Wegovy and Zepbound are approved for adults with obesity, or with overweight and at least one weight-related health condition, alongside a reduced-calorie diet and more physical activity. The heart, kidney, liver and sleep apnea approvals above each apply to a specific group of people. Whether one fits you depends on your weight, your health history and what you want to change.
Your goal, with a physician beside you
If you're reading about GLP-1s for longevity, you probably want the same things most people do: a healthy heart, steady blood sugar, strength that lasts and energy for the years ahead. That's where our physicians focus.
- Aayu Elevate™: video visits with an obesity medicine physician, a registered dietitian, and medicine when it's right for you.
- Aayu Elevate Plus™: everything in Elevate, plus care for common conditions such as depression, anxiety and sleep problems.
Your physician looks at the whole picture, including weight, blood pressure, cholesterol, blood sugar, kidney function and sleep, and tells you plainly whether a GLP-1 medicine makes sense for you. Your dietitian helps you get enough protein and keep your muscle while the weight comes off. Most major insurance accepted, plus convenient cash pay options. Book my consultation
Questions to bring to your visit
- Do I qualify for a GLP-1 medicine, and which one fits my health?
- Would one lower my risk for the conditions I'm most worried about?
- How do I protect my muscle while I lose weight?
- What side effects should I watch for, and what happens if I stop?
- Which of my labs should we check first? See longevity labs after 40.
Good to know
- Side effects. The most common ones on the Wegovy label are stomach and bowel symptoms, headache, tiredness, dizziness and hair loss. In SELECT, 16.6% of people on semaglutide stopped because of side effects, compared with 8.2% on placebo.
- Label warnings. Your physician will go over them with you, including a boxed warning about thyroid C-cell tumors, pancreatitis and gallbladder problems.
- Brand-name medicines were studied. The trials on this page tested the brand-name medicines. Compounded versions are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold.
Where peptides and other longevity products fit
You may also see peptides, NAD+ and supplements marketed for healthy aging. So far, none has trial results in people like the ones above. Our peptide guide grades the evidence for each one, and our healthy aging guide covers the habits with the strongest evidence.
Questions people ask
Can an Aayu Well physician tell me whether a GLP-1 is right for me?
Yes. In a video visit, an obesity medicine physician looks at your weight, heart, kidneys, blood sugar, sleep and the medicines you take, and tells you plainly whether a GLP-1 medicine fits your health. If it does, it becomes part of a plan with a registered dietitian. If it doesn't, you still leave with a plan.
Do GLP-1 medicines help you live longer?
We don't know yet for healthy people. In trials of people with heart disease or with diabetes and kidney disease, fewer people taking semaglutide had heart attacks, strokes or serious kidney events. In the kidney trial, fewer died of any cause during the study. No trial has tested GLP-1 medicines in healthy people as a way to live longer.
Is Wegovy approved to protect the heart?
Yes, for a specific group. Wegovy's FDA label includes lowering the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and either obesity or overweight.
Will I lose muscle on a GLP-1?
Some of the weight you lose is lean tissue, including muscle. Studies differ widely on how much. Enough protein and regular strength training help you keep it, and a registered dietitian can help you plan both.
What happens if I stop?
Weight often comes back after people stop a GLP-1 medicine, which is one reason expert groups stress nutrition and activity habits from the start. Talk with your physician before you stop or change your dose.
Find out what a GLP-1 could do for your health
In one video visit, an obesity medicine physician looks at your weight, heart, kidneys, blood sugar and sleep, tells you whether a GLP-1 medicine fits your health, and builds a plan with you. Most major insurance accepted, plus convenient cash pay options.
Sources
- WEGOVY (semaglutide) prescribing information, Indications and Usage, Highlights and Warnings and Precautions (DailyMed, revised 6/2026)
- OZEMPIC (semaglutide) prescribing information, Indications and Usage (DailyMed, revised 5/2026)
- ZEPBOUND (tirzepatide) prescribing information, Indications and Usage (DailyMed, revised 8/2026)
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
- Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099.
- Kosiborod MN, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084.
- Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437.
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 10/01/2026)
